?

Hepatitis Market Research Reports & Industry Analysis

The notion “hepatitis” means inflammation of the liver or its cells, often caused by some virus and accompanied in its initial phase to by symptoms similar to flu: fever, loss of appetite, muscle/joint aches, etc. According to the virus type hepatitis is divided into several types: hepatitis A, В C, D and E. Hepatitis can disappear on its own, but in some cases it can lead to serious liver dysfunctions and severe complications such as fibrosis, liver failure or cancer, cryoglobulinemia, an a lot more.

The world hepatitis drugs market has experienced stable growth over the recent years, driven by the constant increase of demand from developed countries, introduction of new products and technological advancement in the medical industry. It is set to continue growing at a CARG of above 12% through 2015. Gilead Sciences, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb and Hoffmann-La Roche are amid the key hepatitis market players.

The collection of the research reports found in this catalogue provides an extensive insight into the hepatitis market at different geographical scales. Relevant information on the market size, share, segmentation as well as major factors influencing the market is presented in the researches. The reports offer detailed assessment of the competitive landscape and profile top companies. In addition, discussions of future market prospects for the are at hand in the research reports.

Found 93 publications
2015-2019 US Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic... US$ 3,900.00

... Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ... In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the ...

Jun, 2015 241 pages
2015-2019 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ... In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the ...

Jun, 2015 241 pages
2015-2019 Spanish Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume ...

Jun, 2015 241 pages
2015-2019 Japanese Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs - Supplier Shares and Sales Forecasts for 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume ...

Jun, 2015 241 pages
2015-2019 Italian Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume ...

Jun, 2015 241 pages
2015-2019 German Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume ...

Jun, 2015 241 pages
2015-2019 French Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs - Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume ...

Jun, 2015 241 pages
2015-2019 European Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 6,900.00

... $6,900. DataPack (test volumes, sales forecasts, supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the Hepatitis definition, epidemiology and etiology ...

Jun, 2015 295 pages
2015-2019 World Hepatitis Markers Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies, Opportunities for Suppliers - France, Germany,... US$ 9,500.00

... , Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: Hospitals Commercial ... , in addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the ...

Jun, 2015 295 pages
2015 Strategies in the US Hepatitis Diagnostic Testing Market US$ 3,900.00

... ; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues ...

May, 2015 241 pages
2015 Strategies in the UK Hepatitis Diagnostic Testing Market US$ 3,900.00

... ; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues ...

May, 2015 241 pages
2015 Strategies in the Spanish Hepatitis Diagnostic Testing Market US$ 3,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 241 pages
2015 Strategies in the Japanese Hepatitis Diagnostic Testing Market US$ 3,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 241 pages
2015 Strategies in the Italian Hepatitis Diagnostic Testing Market US$ 3,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 241 pages
2015 Strategies in the German Hepatitis Diagnostic Testing Market US$ 3,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific views on the Hepatitis definition, epidemiology and ... identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 241 pages
2015 Strategies in the French Hepatitis Diagnostic Testing Market US$ 3,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific views on the Hepatitis definition, epidemiology and ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 241 pages
2015 Strategies in the European Hepatitis Diagnostic Testing Market US$ 6,900.00

... report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the ... and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning ...

May, 2015 295 pages
2015 Strategies in the Global Hepatitis Diagnostic Testing Market US$ 9,500.00

... ; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues ...

May, 2015 320 pages
Alcoholic Hepatitis Global Clinical Trials Review, H1, 2015 US$ 2,500.00

... Alcoholic Hepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Alcoholic Hepatitis. It includes an overview of the trial numbers and their recruitment ...

Jan, 2015 64 pages
Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates US$ 260.00

Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf ...

Jan, 2015 25 pages
Hepatitis D Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Hepatitis D clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis D. It includes an overview of the trial numbers and their recruitment ...

Nov, 2014 58 pages
2014-2014 US Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic... US$ 3,900.00

... Hospitals Commercial/Private Labs Blood Banks Physician Offices Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, ...

Nov, 2014 241 pages
2014-2018 European Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10... US$ 6,900.00

... , supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific ... presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA ...

Nov, 2014 295 pages
Global Hepatitis C Market 2014-2018 US$ 3,000.00 US$ 2,400.00

... scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated ... administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus. TechNavio's report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from ...

Sep, 2014 104 pages
Alcoholic Hepatitis - Pipeline Review, H1 2015 US$ 2,000.00

Alcoholic Hepatitis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Alcoholic Hepatitis - Pipeline Review, H1 2015’, provides an overview of the Alcoholic Hepatitis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis ...

Mar, 2015 56 pages
2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... markets: Hospitals Commercial/Private Labs Blood Banks Public Health Labs In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal ...

Nov, 2014 241 pages
2014-2014 Spanish Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...

Nov, 2014 241 pages
2014-2014 Italian Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...

Nov, 2014 241 pages
2014-2014 German Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...

Nov, 2014 241 pages
2014-2014 French Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...

Nov, 2014 241 pages
2014-2014 Japanese Hepatitis Markers Testing Market: Hospitals, Blood Banks, Commercial Labs--Supplier Shares and Sales Forecasts for 10 Immunodiagnostic and NAT Procedures US$ 3,900.00

... $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific ... , epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, ...

Nov, 2014 241 pages
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape US$ 4,995.00

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage ... , “Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment ...

Jan, 2014 120 pages
Therapy Class Overview : Hepatitis C Virus Infection US$ 1,000.00

... (PhIII) and AbbVie/ Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well! Tapping the ... and ROW opportunity Competitive Landscape - IFN-Free drugs HCV Vaccines and their progress Difficult to treat and drugs for HCV-HIV co infection Market size opportunity ...

Oct, 2013 33 pages
US Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT... US$ 3,900.00

... , sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the ... HBV NAT , HBs Ag, HCV , Anti-HBc , Anti-HBs , Anti-HAV , Hepatitis Delta , HBc Ag , HBe Ag , and ALT/SGPT tests performed in the ...

Jan, 2014 241 pages
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight US$ 7,495.00

... represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the ... will shape the future market. Key Benefits Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained ...

Apr, 2014 163 pages
Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook US$ 7,495.00

... effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that ... significant market event. Key Benefits Therapy Trends Consensus Outlook: Hepatitis C provides: Evaluate future sales forecasts and predicted market growth ...

Dec, 2013
European Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and... US$ 6,900.00

... , supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the ... , HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...

Jan, 2014 295 pages
2014 Opportunities in the US Hepatitis Diagnostic Testing Market US$ 3,900.00 US$ 3,315.00

... analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Contains 241 ...

Dec, 2013 241 pages
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C? US$ 695.00

... currently anticipated for AbbVie. To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious ... of genotype 1 patients they would prescribe an interferon-sparing, once-daily, single-tablet therapy rather than an interferon-sparing multi-tablet therapy dosed ...

Nov, 2013
2014 Analysis of the European Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 6,900.00 US$ 5,865.00

Complete report $6,900. DataPack (test volumes, sales forecasts, supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. ...

Nov, 2013 295 pages
2014 Analysis of the US Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00 US$ 3,315.00

Complete report $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Nov, 2013 241 pages
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ... Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Vaniprevir including ...

May, 2013 48 pages
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic ... of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Sofosbuvir and Sofosbuvir/Ledipasvir including ...

May, 2013 55 pages
Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease ... Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Simeprevir including ...

May, 2013 51 pages
Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic ... of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Faldaprevir and BI 207127 including ...

May, 2013 51 pages
Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

... information on Daclatasvir, Asunaprevir, and Peginterferon Lambda including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda for the ... from insightful and in-depth analysis of Daclatasvir, Asunaprevir, and Peginterferon Lambda performance Obtain sales forecast for Daclatasvir, Asunaprevir, and Peginterferon Lambda from 2012-2022 in top nine countries ...

May, 2013 52 pages
AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary ... from insightful and in-depth analysis of ABT-450, ABT-333, and ABT-267 performance Obtain sales forecast for ABT-450, ABT-333, and ABT-267 from 2012-2022 in top ...

May, 2013 50 pages
Hepatitis C Drug Pipeline Analysis US$ 1,800.00

... when purchasing Hard Copy License depending on the location. “Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, ...

Aug, 2013 700 pages
Hepatitis Drugs and Vaccines: World Market 2013-2023 US$ 2,635.00

... . What prospects for regions and countries? Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. ... you possibilities, helping you stay ahead. Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you To sum up, our ...

Jun, 2013 197 pages
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide US$ 2,090.00

... C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability ... HCV have been identified as a formidable challenge to prevention and care. Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, ...

Jul, 2013 164 pages
1 2 >
Skip to top